Objective: This study seeks to assess the effectiveness of cyclosporine and methotrexate in treating severe psoriasis, an autoimmune condition characterized by the formation of thick, red, scaly patches on the skin that recur over time. These two medications have been the gold standard for treating severe psoriasis for many years. This study’sobjective is to provide a comprehensive evaluation of their clinical outcomes as potential treatment options. Methods: To gain insights into the treatment of severe psoriasis, this study conducted a retrospective analysis of medical records over three years for hospitalized patients. The study evaluating the effectiveness of methotrexate and cyclosporine in treating severe psoriasis examined various outcomes, including the Psoriasis Area and Severity Index (PASI) and length of hospital stay (LOS). This information is valuable in guiding clinicians toward the most effective management of this chronic autoimmune disease. Results:Both methotrexate and cyclosporine were successful in lowering the psoriasis area and severity index in the study of 26 individuals with severe psoriasis (PASI). The average PASI decrease was 42.8% (or 24.64). In contrast to those who received methotrexate (mean 43.2224.4%), individuals who received cyclosporine had a higher decrease in PASI (mean 54.88±12.73%). The cyclosporine group required more time in the hospital 18.83 days with ±9.39 standard deviation than the methotrexate group which had 11.65 of hospital stay with ±5.91 standard deviation while having a better decrease in PASI. Conclusions: The study demonstrated the efficacy of methotrexate and cyclosporine as treatments for extreme psoriasis. However, patients treated with cyclosporine may require longer hospital stays compared to those treated with methotrexate.

cyclosporine, methotrexate, psoriasis